BioSpace News Archive

Artelo Biosciences, Inc. (NASDAQ:ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the Virtual Fall Investor Summit to be held virtually on November 16-18, 2020. Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present on Wednesday, November 18

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will present at two upcoming virtual investor conferences.

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that its Special Meeting of Stockholders, scheduled for October 22, 2020 and adjourned to November 11, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved on the proposals to be approved.

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), announce that the Sputnik V vaccine, the world’s first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors,

Perspectum® will be unveiling new data at The Liver Meeting® 2020, with two oral presentations and six posters highlighting both the utility and diagnostic accuracy of LiverMultiScan®, as well as the link between NAFLD and the increasing risk of hospitalization with severe COVID-19.

Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.